OTSUKA PHARMACEUTICAL DEVELOPMENT & COMMERCIALIZATION, INC.
🇺🇸United States
Efficacy & Safety Study of Once-weekly Oral Aripiprazole in Children and Adolescents With Tourette's Disorder
- First Posted Date
- 2011-08-17
- Last Posted Date
- 2021-10-07
- Target Recruit Count
- 135
- Registration Number
- NCT01418339
Safety and Tolerability Study of Once-weekly Oral Aripiprazole in Children and Adolescents With Tourette's Disorder
- First Posted Date
- 2011-08-15
- Last Posted Date
- 2021-10-07
- Target Recruit Count
- 170
- Registration Number
- NCT01416441
Safety and Tolerability Study of Oral OPC-34712 as Maintenance Treatment in Adults With Schizophrenia
- First Posted Date
- 2011-07-20
- Last Posted Date
- 2017-05-10
- Target Recruit Count
- 1044
- Registration Number
- NCT01397786
Study of the Effectiveness of Three Different Doses of OPC-34712 in the Treatment of Adults With Acute Schizophrenia
Phase 3
Completed
- Conditions
- Acute Schizophrenia
- Interventions
- Drug: OPC-34712 [Brexpiprazole] High DoseDrug: Placebo
- First Posted Date
- 2011-07-18
- Last Posted Date
- 2015-10-29
- Target Recruit Count
- 636
- Registration Number
- NCT01396421
Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer
- First Posted Date
- 2011-07-15
- Last Posted Date
- 2016-04-08
- Target Recruit Count
- 202
- Registration Number
- NCT01395017
Efficacy Study of OPC-34712 in Adults With Acute Schizophrenia
- First Posted Date
- 2011-07-13
- Last Posted Date
- 2015-11-26
- Target Recruit Count
- 674
- Registration Number
- NCT01393613
Safety and Tolerability of Oral OPC-34712 as Adjunctive Therapy in Adults With Major Depressive Disorder (the Orion Trial)
Phase 3
Completed
- Conditions
- DepressionDepressive Disorder, MajorDepressive DisorderMood DisordersMental Disorders
- Interventions
- First Posted Date
- 2011-05-26
- Last Posted Date
- 2018-09-17
- Target Recruit Count
- 2944
- Registration Number
- NCT01360866
- Locations
- 🇺🇦
Research Site, Poltava, Ukraine
Study of the Safety and Efficacy of Two Fixed Doses of OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder (the Polaris Trial)
Phase 3
Completed
- Conditions
- Depressive DisorderDepressionDepressive Disorder, MajorMood DisordersMental Disorders
- Interventions
- Drug: OPC-34712 + ADTDrug: Placebo + ADT
- First Posted Date
- 2011-05-25
- Last Posted Date
- 2016-01-01
- Target Recruit Count
- 1539
- Registration Number
- NCT01360632
- Locations
- 🇺🇦
Research Site, Poltava, Ukraine
Study of the Safety and Efficacy of Fixed Dose OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder (the Pyxis Trial)
Phase 3
Completed
- Conditions
- Mood DisordersDepressive Disorder, MajorMental DisordersDepressionDepressive Disorder
- Interventions
- Drug: OPC-34712 + ADTDrug: Placebo + ADT
- First Posted Date
- 2011-05-25
- Last Posted Date
- 2015-11-26
- Target Recruit Count
- 826
- Registration Number
- NCT01360645
- Locations
- 🇸🇰
Research Site, Michalovce, Slovakia
Short-term Renal Hemodynamic Effects of Tolvaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
- First Posted Date
- 2011-04-18
- Last Posted Date
- 2019-03-05
- Target Recruit Count
- 29
- Registration Number
- NCT01336972
- Locations
- 🇳🇱
University Medical Center Groningen, Groningen, Netherlands
© Copyright 2025. All Rights Reserved by MedPath